[go: up one dir, main page]

WO2004001055A2 - Promedicaments a base de pna - Google Patents

Promedicaments a base de pna Download PDF

Info

Publication number
WO2004001055A2
WO2004001055A2 PCT/DK2003/000416 DK0300416W WO2004001055A2 WO 2004001055 A2 WO2004001055 A2 WO 2004001055A2 DK 0300416 W DK0300416 W DK 0300416W WO 2004001055 A2 WO2004001055 A2 WO 2004001055A2
Authority
WO
WIPO (PCT)
Prior art keywords
pna
compound
acid
tools
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000416
Other languages
English (en)
Other versions
WO2004001055A3 (fr
Inventor
Nadia Bendifallah
Peter Eigil Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Priority to AU2003240435A priority Critical patent/AU2003240435A1/en
Publication of WO2004001055A2 publication Critical patent/WO2004001055A2/fr
Publication of WO2004001055A3 publication Critical patent/WO2004001055A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Definitions

  • the present invention concerns novel drugs for use in combating various diseases. More particular, the invention concerns peptide nucleic acid (PNA) prodrugs and methods for their preparation.
  • PNA peptide nucleic acid
  • Antisense agents offer a novel strategy in combating diseases, as well as opportunities to employ new chemical classes in the drug design.
  • Oligonucleotides can interact with native DNA and RNA in several ways. One of these is duplex formation between an oligonucleotide and a single stranded nucleic acid. Another is triplex formation between an oligonucleotide and double stranded DNA to form a triplex structure.
  • PNAs Peptide nucleic acids
  • PNA Peptide nucleic acids
  • the deoxyribose backbone of oligonucleotides has been replaced by a pseudo-peptide backbone (Nielsen et al. 1991 (1 )).
  • Each subunit, or monomer has a naturally occurring or non-naturally occurring nucleobase attached to this backbone.
  • One such backbone is constructed of repeating units of N-(2-aminoethyl)glycine linked through amide bonds.
  • PNA hybridises with complementary nucleic acids through Watson and Crick base pairing and helix formation (Egholm et al. 1993 (2)).
  • the pseudo-peptide backbone provides superior hybridization properties (Egholm et al. 1993 (2)), resistance to enzymatic degradation (Demidov et al. 1994 (3)) and access to a variety of chemical modifications (Nielsen and Haaima 1997 (4), WO 94/25477, WO 98/03542).
  • PNA binds both DNA and RNA to form PNA/DNA or PNA/RNA duplexes.
  • the resulting PNA/DNA or PNA/RNA duplexes are bound with greater affinity than corresponding DNA/DNA or DNA/RNA duplexes as determined by the melting point temperature (Tm).
  • Tm melting point temperature
  • PNA has also been shown to bind to DNA with increased specificity. When a PNA/DNA duplex mismatch is melted relative to the DNA/DNA duplex, there is seen an 8 to 20°C drop in the melting point temperature.
  • PNA oligomers form extremely stable PNA 2 - DNA (RNA) triplexes with sequence complementary targets in DNA or RNA oligomers.
  • PNAs may bind to double stranded DNA or RNA by helix invasion.
  • PNA polyamide backbone (having appropriate nucleobases or other side chain groups attached thereto) is not recognised by either nucleases or proteases and are thus not cleaved.
  • PNAs are resistant to degradation by enzymes unlike nucleic acids and peptides.
  • PNAs can be used as a tool in molecular biology and biotechnology, for diagnostic purposes and development, but it is also a lead compound for the development of gene-targeted drugs applying antigene or antisense strategy.
  • target bound PNAs can cause steric hindrance of DNA and RNA polymerases, reverse transcription, telomerase and of the ribosomes (Hanvey et al. 1992 (5), Knudsen et a. 1996 (6), Good and Nielsen 1998 (7,8)) by targeting among others DNA, mRNA, rRNA, or tRNA.
  • the sequence-specific inhibition by PNAs could potentially be exploited for therapeutic applications.
  • cellular delivery of the PNA is required for antigene and antisense applications. Previous work has shown that cells only poorly take up naked PNA. Within the last couple of years a variety of methods have been devised to address this problem.
  • WO 99/05302 discloses a PNA conjugate consisting of PNA and the carrier peptide transportan, which peptide may be used for transport across a lipid membrane for delivery of the PNA to intracellular targets.
  • US-A-5 777 078 discloses a pore-forming compound, which comprises a delivery agent recognising the target cell and being linked to a pore-forming agent, such as a bacterial exotoxin.
  • the compound is administered together with a drug such as PNA.
  • WO 96/11205 discloses PNA conjugates, wherein a conjugated moiety may be placed on terminal or non-terminal parts of the backbone of PNA in order to functionalise the PNA.
  • the conjugated moieties may be reporter enzymes or molecules, steroids, carbohydrate, terpenes, peptides, proteins, etc. It is suggested that the conjugates among other properties may possess improved transfer properties for crossing cellular membranes.
  • WO 98/52614 discloses a method of enhancing transport over biological membranes.
  • biological active agents such as PNA may be conjugated to a transporter polymer in order to enhance the transmembrane transport.
  • the transporter polymer consists of 6-25 subunits; at least 50% of which contain a guanidino or amidino sidechain moiety and wherein at least 6 contiguous subunits contain guanidino and/or amidino sidechains.
  • a preferred transporter polymer is a polypeptide containing 9 arginine ((Arg) 9 ).
  • oligonucleotide prodrug reactive with a cellular or tissue enzyme which cleaves the lipophilic group from the derivatised nucleotide, thereby regenerating the parent oligonucleotide is disclosed in WO96/07392.
  • the oligonucleotide prodrug comprises at least six covalently linked nucleotides, at least one of which is derivatised with a lipophilic chemical group containing an ester or amide covalently attached to the nucleotide at a 5' phosphate, 3' phosphate, or an intemucleotidic phosphate linkage.
  • PNA prodrugs need only to possess the effect of promoting the transport of PNAs across membranes, with subsequent cleaving off the carrier from the PNA antisense-targeting group, at the target site.
  • the present invention relates to novel Peptide Nucleic Acid (PNA) prodrugs comprising a suitable carrier attached to the PNA through an in vitro stable, enzymatically cleavable moiety, allowing cellular delivery of PNA prodrugs.
  • PNA prodrugs exhibit enhanced transport across cell membranes with subsequent intracellular liberation of the PNA by intracellular processes, thereby improving the access of the PNA to potential targets such as mRNA, rRNA, tRNA or DNA.
  • PNA prodrugs of the present invention achieves a different intracellular distribution as compared to non-cleavable PNA drugs, as the released PNA appear to be nuclear associated although without full nuclear localisation.
  • Such a nuclear localisation is advantageous for antigene- targeting and antisense-targeting of exon-intron splice junctions.
  • the present invention relates to a modified PNA prodrug of formula (I)
  • Q is a carrier moiety
  • E is a cleavable moiety
  • Li and L 2 are, independently, a linker or a bond
  • PNA is a peptide nucleic acid oligomer.
  • E is an amino acid of the formula (II)
  • X and Y are preferably an alkylene group, a C 2 -n- alkenylene, a C ⁇ n-alkynylene, a phenylene group, or a benzylidene group.
  • the ester bond is sensitive to cleavage by an enzyme.
  • the - A - B -- is a group of formula (IV)
  • the carrier moiety is linked to the PNA sequence via the amino (N-terminal) or carboxy (C-terminal) end.
  • the PNA prodrug of the invention is prepared from an amino acid of the formula (V)
  • R 1 is H, Boc, Fmoc or other suitable solid phase protecting groups
  • R 2 is -OH, -OR 3 , -SR 3 , -OCOR 3 ,
  • R 3 is an alkyl, a C 2 - n -alkenyl, a C 2 - n -alkynyl, an aryl, or an alkylaryl, R 4 is H, F, Cl, or Br and R 5 is H, or -SO 3 H.
  • a method of synthesising a PNA prodrug of the invention comprising cleavable moieties by use of solid-phase synthesis is claimed.
  • Medical applications of the compounds of the present invention include treatment or prevention of bacterial, viral, protozoal, and fungal infections, cancer, metabolic diseases, cardiovascular diseases, autoimmune and immunological disorders.
  • PNA prodrugs that bind to targets in single stranded and double stranded DNA as well as to mRNA, rRNA and tRNA by a variety of mechanisms may be developed into antigene or antisense drugs by targeting specific sequences of specific genes. In this way the expression of the targeted gene can be inhibited, or in desired cases activated, and the level of a disease related gene product thereby regulated.
  • alkyl group refers to a C ⁇ - n -alkyl, wherein n' can be from 2 through 15, representing a branched or straight alkyl group having from one to the specified number of carbon atoms.
  • Typical C- ⁇ - 6 -alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso- propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, iso-hexyl saturated as well as non-saturated groups.
  • C 2 - n -alkenyl wherein n' can be from 3 through 15, as used herein, represents an olefinically unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one double bond.
  • groups include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, allyl, iso-prophenyl, 1 ,3-butadienyl, 1-butenyl, hexenyl, pentenyl, and the like.
  • n '-alkynyl wherein n' can be from 3 through 15, as used herein, represent an unsaturated branched or straight group having from 2 to the specified number of carbon atoms and at least one triple bond.
  • examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1- butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl and the like.
  • aryl group refers to an aryl including aromatic rings, such as carboxylic aromatic rings selected from the group consisting of phenyl, naphthyl, (1-naphtyl or 2-naphtyl) optionally substituted with halogen, amino, hydroxy, Ci- ⁇ -alkyl or C- ⁇ - 6 -alkoxy.
  • alkylaryl group refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic carbohydride; such as benzyl, phenethyl, 3-phenylpropyl, 1- naphtylmethyl, 2-(1-naphtyl)ethyl and the like.
  • a charge neutral oligomer of the present invention refers to the charge neutral backbone of the PNA oligomer, comprising N-(2- aminoethyl)glycine.
  • Figure 1 IMR-92 cellular uptake of the synthesized PNA-3 drug (non- cleavabgle) and PNA-5 prodrug (cleavable) compared to the control.
  • PNA prodrugs exhibiting enhanced cellular uptake and distribution are provided.
  • the PNA prodrugs are assembled from a suitable carrier attached to the PNA by a among others, a cleavable moiety, whereby the carrier is cleaved off from the PNA following transport across cell membranes, thereby preventing intracellular entrapment of the PNA in lipid or other compartments inside the cell.
  • the PNA prodrugs of the present invention have the formula (I), wherein E is the cleavable moiety.
  • the cleavable moiety comprises an ester.
  • the PNA prodrug of the present invention may be used in other PNA conjugates such as defined in the PCT Publication WO 01/27261 enhancing the cellular distribution and nuclear association of the PNA.
  • a method of synthesising PNA prodrugs of the invention comprising cleavable moieties, by use of solid- phase synthesis is claimed.
  • PNA oligome sation involves rather harsh acid and/or alkaline treatment.
  • the cleavable moieties are easily incorporated into PNA prodrugs using solid phase polymerisation, deprotection and cleavage conditions.
  • a necessary precaution to be taken is the employment of carefully dried ether for precipitation of the product after cleavage from the resin, in order to avoid hydrolysis of the cleavable moieties.
  • Fragment coupling is an alternative method of producing compounds of the invention.
  • the carrier moiety containing an -SH function e.g. a cystein
  • the carrier moiety may be fragment- coupled to the cleavable linker by applying e.g. succinimidyl 4-[N- maleimidomethyl]-cyclohexan-1-carboxylat (SMCC).
  • SMCC succinimidyl 4-[N- maleimidomethyl]-cyclohexan-1-carboxylat
  • Other coupling chemistries known to the skilled artisan may also be applied (Wong 1993 (23)).
  • the PNA prodrugs of the present invention are used in the manufacture of medicaments for the treatment or prevention of bacterial, viral, protozoal, and fungal infections, cancer, metabolic diseases, cardiovascular diseases, autoimmune and immunological disorders, or for disinfecting non-living objects, such as surgery tools, hospital inventory, dental tools, slaughterhouse inventory and tool, dairy inventory and tools, barbers and beauticians tools and the like.
  • the compounds of the invention may be prepared in the form of pharmaceutically acceptable salts, especially acid- addition salts, including salts of organic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, benzoic acid, salicylic acid, and the like.
  • Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric- and phosphoric acids and the like.
  • Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, Berge et al 1977 (19), which are known to the skilled artisan.
  • Also intended as pharmaceutically acceptable acid-addition salts are the hydrates, which the present compounds are able to form.
  • the acid-addition salts may be obtained as the direct prodrugs of compound synthesis.
  • the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
  • the compounds of this invention may form solvates with standard low molecular weight solvents using methods known to the skilled artisan.
  • the invention concerns the manufacture of a composition for treating or preventing bacterial, viral, protozoal, and fungal infections, cancer, metabolic diseases, cardiovascular diseases, autoimmune and immunological disorders, or disinfecting non-living objects, such as surgery tools, hospital inventory, dental tools, slaughterhouse inventory and tool, dairy inventory and tools, barbers and beauticians tools and the like.
  • compositions include a compound of the invention or a pharmaceutically acceptable acid-addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier, which can be in the form of a capsule, sachet, paper or other container.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier, which can be in the form of a capsule, sachet, paper or other container.
  • the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper, or other container.
  • the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material, which acts as a vehicle, excipient, or medium for the active compound.
  • the active compound can be adsorbed on a granular solid container for example in a sachet.
  • suitable carriers are water, salt solutions, alcohol's, polyethylene glycol's, polyhydroxyethoxylated castor oil, peanut oil, olive oil, glycine, gelatin, lactose, terra alba, sucrose, glucose, cyclodextrine, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, thickeners or flavoring agents.
  • the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or coloring substances and the like, which do not deleteriously react with the active compounds.
  • the PNA prodrug of the invention can be formulated in a pharmaceutical composition, which may include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anaesthetics, and the like in addition to PNA.
  • the pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be done topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip or subcutaneous, intraperitoneal or intramuscular injection.
  • Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms may also be useful.
  • compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavourings, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • the preparation may be tabletted placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • a liquid carrier is used, the preparation may be in the form of a suspension or solution in water or a non-aqueous media, a syrup, emulsion or soft gelatin capsules. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be added.
  • Formulations for parenteral administration may include sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.
  • the preparation may contain a compound of the invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilising agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrine, or preservatives such as parabenes.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
  • Preferable carriers for tablets, dragees, or capsules include lactose, cornstarch, and/or potato starch.
  • a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
  • the invention concerns the treatment or prevention of bacterial, viral, protozoal, and fungal infections, cancer, metabolic diseases, cardiovascular diseases, autoimmune and immunological disorders, or treatment of non-living objects.
  • Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several days to several months or until a cure is effected or a diminution of disease state is achieved. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.
  • dosage forms suitable for oral, nasal, pulmonal or transdermal administration comprise from about 0.01 mg to about 500 mg, preferably from about 0.01 mg to about 100 mg of the compounds of the invention admixed with a pharmaceutically acceptable carrier or diluent.
  • Treatments of this type can be practiced on a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.
  • Any organism that utilises DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated.
  • each cell of multicellular eukaryotes can be treated since they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity.
  • many of the organelles, e.g.
  • mitochondria and chloroplasts of eukaryotic cells also include transcription and translation mechanisms.
  • single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic PNA prodrug.
  • therapeutics is meant to include the eradication of a disease state, by killing an organism or by control of erratic or harmful cellular growth or expression.
  • the reagents used were Phtalid (Aldrich), 1 ,3-dicyclohexylcarbodiimide (DCC, Aldrich), N-t-Boc-Glycine (Sigma), 4-dimethylaminopyridine (DMAP, Aldrich), 1-pyrenebutyhc acid (Aldrich), Decanoic acid (Deca, Aldrich), 1- Adamantaneacetic acid (Ada, Aldrich). TLC was performed on silica 60 (Merck 5554 aluminium sheet), dichloromethane (LAB-SCAN), and diethyl ether (LAB-SCAN). The two last mentioned were dried over molecular sieves before use.
  • Ada 1 -adamantaneacetic acid
  • Ado 8-amino-3,6-dioxa-octanoic acid (alias eg-i)
  • DMEM Dulbecco's Modified Eagle's Medium
  • DMSO Dimethyl sulfoxide FI Lys- Fluorescein Lysin monomer (6-0-[N-5-Boc-amino-5- carboxypentyl)carbamoylmethyl]fluorescein ethyl ester)
  • PBS Phosphate-buffered saline
  • Phtalide (5.0 g, 37.28 mmol) was dissolved in methanol (20 mL) and water (20 mL). NaOH (10 M, 8 ml) was added, and the mixture was refluxed for 90 min. The reaction mixture was then cooled to room temperature, and the free acid was precipitated with 4 M HCI (ca. 10 ml). The resulting precipitate was filtered off, washed with ice-cold water and finally dried in vacuo to give a white crystalline product (5.03 g, 89 %). Melting point (M.p.): 101-105 °C (litt. 120.5-121.5 °C).
  • a symmetrical anhydride was formed from N-Boc-glycine (7.72 g, 44.06 mmol) and DCC (4.55 g, 22.03 mmol) in dry dichloromethane (25 ml). The mixture was stirred at 0°C for 30 min. The resulting N,N'-dicyclohexylurea (DCU) was filtered off and the filtrate was added directly to a suspension of 2-hydroxymethylbenzoic acid (Gilman et al 1940 (20)) in dry dichloromethane (25 ml). DMAP (0.19 g, 1.54 mmol) was added and the mixture was refluxed overnight.
  • DCU N,N'-dicyclohexylurea
  • PNA-1 Pyr-BMB2-TJ-ado-ado-ado-CTTTCTT-NH 2
  • PNA-2 Deca-ado-FI L y S -ado-CATAGTATAAGT-LysNH 2
  • PNA-3 Ada-ado-FI Lys -ado-CATAGTATAAGT-LysNH 2
  • PNA-4 Deca-BMB2- ado-FI Lys -ado-CATAGTATAAGT-LysNH 2
  • PNA-5 Ada- BMB2-ado-FI L y S -ado-CATAGTATAAGT-LysNH 2
  • PNA-1 Pyr-BMB2-TJ-ado-ado-ado-CTTTCTT-NHg
  • the PNA prodrug was synthesised on a Boc-T-4-methylbenzhydrylamine resin (loading 0.12 mmol/g) using the standard synthetic protocol.
  • the coupling was allowed to proceed for 60 min.
  • the resulting PNA prodrug was deprotected and cleaved from the resin with a cocktail composed of m-cresol/thioanisole/trifluoromethane sulfonic acid/TFA (1/1/2/6, v/v) and the crude material was precipitated and washed with anhydrous diethylether.
  • the PNA prodrugs were then purified by reversed-phase high performance liquid chromatography (HPLC) and characterised by MALDI-TOF mass spectroscopy.
  • PNA-2 Deca-ado-F ys -ado-CATAGTATAAGT-LvsNH?
  • the PNA drug was synthesised on a Boc-L-Lys(2-chlorobenzyloxycarbonyl)- 4-methylbenzhydrylamine resin (loading 0.15 mmol/g) using the standard synthetic protocol (Christensen et al 1995 (21 )).
  • the standard synthetic protocol Christensen et al 1995 (21 )
  • the fluorescein-lysin monomer (6-O-[N-(5-Boc-amino-5- carboxypentyl)carbamoylmethyl]fluorescein ethyl ester) (Lohse et al 1997 (22)
  • the coupling was allowed to proceed for 60 min.
  • the resulting PNA drug was deprotected and cleaved from the resin with a cocktail composed of m-cresol/thioanisole/thfluoromethane sulfonic acid/TFA (1/1/2/6, v/v) and the crude material was precipitated and washed with anhydrous diethylether.
  • the PNA drug was then purified by reversed-phase HPLC and characterised by MALDI-TOF mass spectroscopy.
  • PNA-3 Ada-ado-Fli ⁇ -ado-CATAGTATAAGT-LvsNH?
  • the PNA drug was synthesised on a Boc-L-Lys(2-chlorobenzyloxycarbonyl)- 4-methylbenzhydrylamine resin (loading 0.15 mmol/g) using the standard synthetic protocol (Christensen et al 1995 (21)).
  • 1- adamantaneacetic acid, acid and the fluorescein-lysin monomer (6-O-[N-(5- Boc-amino-5-carboxypentyl)carbamoylmethyl]fluorescein ethyl ester) (Lohse et al 1997 (22)
  • the coupling was allowed to proceed for 60 min.
  • the resulting PNA drug was deprotected and cleaved from the resin with a cocktail composed of m-cresol/thioanisole/trifluoromethane sulfonic acid/TFA (1/1/2/6, v/v) and the crude material was precipitated and washed with anhydrous diethylether.
  • the PNA drug was then purified by reversed-phase HPLC and characterised by MALDI-TOF mass spectroscopy.
  • PNA-4 Deca-BMB2- ado-Fl ⁇ ys -ado-CATAGTATAAGT-LvsNH?
  • the PNA prodrug was synthesised on a Boc-L-Lys(2- chlorobenzyloxycarbonyl)-4-methylbenzhydrylamine resin (loading 0.15 mmol/g) using the standard synthetic protocol (Christensen et al 1995 (21)).
  • decanoic acid 2-([N-Boc-glycyl]oxymethyl)benzoic acid and the fluorescein-lysin monomer (6-O-[N-(5-Boc-amino-5- carboxypentyl)carbamoylmethyl]fluorescein ethyl ester) (Lohse et al 1997 (22)), the coupling was allowed to proceed for 60 min.
  • the resulting PNA prodrug was deprotected and cleaved from the resin with a cocktail composed of m-cresol/thioanisole/trifluoromethane sulfonic acid/TFA (1/1/2/6, v/v) and the crude material was precipitated and washed with anhydrous diethylether.
  • the PNA prodrug was then purified by reversed- phase HPLC and characterised by MALDI-TOF mass spectroscopy.
  • PNA-5 Ada-BMB2-ado-Fl ⁇ y ado-CATAGTATAAGT-LvsNH?
  • the PNA prodrug was synthesised on a Boc-L-Lys(2- chlorobenzyloxycarbonyl)-4-methylbenzhydrylamine resin (loading 0.15 mmol/g) using the standard synthetic protocol (Christensen et al 1995 (21)).
  • the resulting PNA prodrug was deprotected and cleaved from the resin with a cocktail composed of m-cresol/thioanisole/trifluoromethane sulfonic acid/TFA (1/1/2/6, v/v) and the crude material was precipitated and washed with anhydrous diethylether.
  • the PNA prodrug was then purified by reversed- phase HPLC and characterised by MALDI-TOF mass spectroscopy.
  • the synthesised PNAS prodrug Ada-BMB2-ado-FI LYS -CATAGTATAAGT- LysNH 2 .
  • the PNA prodrugs, respective PNA drugs were assembled using a conventional solid phase synthesis on a preloaded 4-(methylbenzhydryl)- amine (MBHA).
  • Fragment coupling is an alternative method of producing compounds of the invention.
  • the carrier moiety containing an -SH function e.g. a cystein
  • the carrier moiety may be fragment coupled to the cleavable linker by applying succinimidyl 4-[N-maleimidomethyf]- cyclohexan-1-carboxylat (SMCC).
  • SMCC succinimidyl 4-[N-maleimidomethyf]- cyclohexan-1-carboxylat
  • Other coupling chemistries known to the skilled artisan may also be applied (Wong 1993 (23)).
  • PNA fragments were diluted in NMP:DMSO (8:2) for 45 min.
  • SMCC diluted in NMP was added with DIEA and the mixture was allowed to react for three hours while stirred.
  • the formed PNA-maleimide conjugate was washed three times with diethylether.NMP (9:1 ) to remove excessive SMCC and subsequently three times with diethylether before dried with nitrogen.
  • the carrier was diluted in 0.1 M NH 4 CO 3 .
  • DTT was added and the mixture was allowed to react for three hours in nitrogen before pH was adjusted to 7.0 by addition of acetic acid.
  • the formed carrier conjugate was separated on a sephadex G-25 gel before mixed with the previous formed PNA-SMCC derivate diluted in DMF. The reaction was stirred over night and the formed PNA prodrug or PNA drug was collected the following day.
  • HPLC separation was performed on a Waters Symmetry 300TM C18, 2.1 x 150 mm (3.5 ⁇ m particles with 300 A pore size) analytical column (Waters) equipped with a Zorbax Eclipse XDB-C18 (5 ⁇ m particles with 80 A pore size) guard column (Agilent) using linear gradient elusion of solvent A (0.1 % TFA in water) and solvent B (0.1% TFA in acetonitrile) from 2% to 75% solvent B over 8 minutes.
  • the column was operated at 50°C. Samples were kept in the autosampler at 5°C. Solvent flow was 0.4 ml/min. Polypropylene (PP) test tubes and containers (Sarsted) were generally used for all solutions containing the test PNA. Samples were centrifuged in a Hettich Rotina 46R centrifuge and evaporated to dryness in a SpeedVac AES 2010 from Savant. NMRI mice (female, 25 g bodyweight) were obtained from M&B (Denmark) for in vivo studies. Plasma and tissue from sacrificed animals were used for in vitro stability/metabolism studies.
  • PP Polypropylene
  • the animal was sacrificed and the relevant tissues (liver, kidneys) rapidly excised.
  • the tissue was immediately placed in 0.25 M sucrose at 0°C for rapid cooling and removal of external blood. After cooling (3-5 min) the tissue was dried by blotting with paper, and subsequently weighed and transferred to clean PP test tubes.
  • To each tissue was added 0.25 M sucrose in water to a final concentration of 150 mg tissue/ml, using a density of 1 mg/ml for the tissue.
  • the tissue was cut into pieces and homogenised for 1-5 min (depending on tissue) in an Ultra-Turrax® T25 homogeniser (IKA) followed by centrifugation of the homogenate in a refrigerated centrifuge (4°C) for 30 minutes at 3000 rpm (corresponding to approx. 1000 x g) to isolate sub- cellular fractions.
  • the supernatant was carefully decanted ( ⁇ the post- mitochondrial supernatant), transferred to polypropylene containers, and stored at minus 80°C
  • a mixture of 0.025 ml in 0.1 M Tris buffer pH 7.4, 0.135 ml of water and 0.025 ml of the tissue homogenate (or plasma) was pre-incubated at 37°C for 2 minutes, before addition of 0.015 ml PNA stock solution (1 mg/ml). After incubation for the desired time period, the enzymatic reactions were stopped by adding 0.300 ml of 16.6% acetonitrile in 0.1% TFA in water, and the sample immediately transferred to an ice-water bath (0°C). The mixture was frozen at minus 18°C for 30 minutes. For analysis, the homogenate mixtures were thawed at 4°C and centrifuged at 3000 rpm for 10 min. (approx.
  • the stability of the PNA-1 prodrug in undiluted tissue homogenates (rat plasma, rat kidney and rat liver) compared to control (Tris buffer, pH 7.4 at 37°C) was estimated to be up to 2000-3000 times less stable (Table 1).
  • the PNA-1 prodrug showed a somewhat limited stability in the buffer with a ty 2 of 6 hours.
  • the IMR-90 cell line (human foetal fibroblast) was obtained from American Type Culture Collection and grown in Dulbecco ' s modified Eagle ' s medium (DMEM) supplemented with penicillin/streptomycin (10 ⁇ g/mL) (antibiotics) and 10% foetal calf serum (Gibco, Invitrogen, Denmark). Cell cultures was maintained at 37°C in a humidified atmosphere containing 5% CO 2 (standard conditions).
  • DMEM Dulbecco ' s modified Eagle ' s medium
  • the cells were cultivated on 4 wells chamber slides (Nunc, Invitrogen, Denmark). The cells were seeded in a concentration of 20 x 10 3 /ml. The following day, the semi confluent cells were prepared for transfection by washing in fresh DMEM containing antibiotics and 2% foetal calf serum. The cells were subsequently added fresh DMEM containing antibiotics and 2% foetal calf serum and incubated 40 minutes at the standard conditions, before replacement of the media with the transfection mixture.
  • the transfection mixture was prepared by diluting 4 ⁇ l of lipofectAMINE (2 mg/ml) (Life Technologies) in 46 ⁇ l DMEM (without serum) and, in a separate tube, diluting PNA in 50 ⁇ l DMEM (without serum) to a final concentration of 4 ⁇ M (approximately 18 ⁇ g/ml).
  • the lipofectAMINE dilution and the PNA dilution was then gently mixed and left for equilibration at room temperature for 30 minutes. 400 ⁇ l DMEM containing antibiotics and 2% foetal calf serum was added to the combined PNA/lipofectAMINE solution and the resulting transfection mixture was gently layered upon the cells.
  • the cells were examined by fluorescence microscopy on an Olympus BX61 microscope. Image analysis was performed using MetaMorph 4.6 (Universal Imaging Corporation) and Adobe Photoshop 4.0 (Adobe Systems Inc.).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne de nouveaux médicaments destinés à lutter contre diverses maladies. Elle concerne plus particulièrement des promédicaments à base de PNA (peptides nucleic acids : acides nucléiques peptidiques), et des procédés permettant de préparer ces promédicaments, ainsi que leurs utilisations pharmaceutiques. Ces promédicaments à base de PNA comprennent un transporteur adéquat fixé sur les PNA par l'intermédiaire d'un segment de liaison clivable. Ce promédicament à base de PNA fait preuve d'un transport amélioré des PNA à travers les membranes cellulaires suivi d'une libération intracellulaire des PNA, améliorant ainsi l'accès des PNA aux cibles cellulaires/nucléaires potentielles.
PCT/DK2003/000416 2002-06-20 2003-06-20 Promedicaments a base de pna Ceased WO2004001055A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003240435A AU2003240435A1 (en) 2002-06-20 2003-06-20 Pna prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200953 2002-06-20
DKPA200200953 2002-06-20

Publications (2)

Publication Number Publication Date
WO2004001055A2 true WO2004001055A2 (fr) 2003-12-31
WO2004001055A3 WO2004001055A3 (fr) 2004-03-18

Family

ID=29797001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000416 Ceased WO2004001055A2 (fr) 2002-06-20 2003-06-20 Promedicaments a base de pna

Country Status (2)

Country Link
AU (1) AU2003240435A1 (fr)
WO (1) WO2004001055A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110361378A (zh) * 2019-07-25 2019-10-22 浙江大学 基于荧光素乙酯的orac抗氧化活性评价方法及荧光指示剂
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENDIFALLAH NADIA ET AL: "Synthesis and properties of ester-linked peptide nucleic acid prodrug conjugates." BIOCONJUGATE CHEMISTRY, vol. 14, no. 3, pages 588-592, XP002260677 ISSN: 1043-1802 (ISSN print) *
BOADO RUBEN J ET AL: "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS" JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 11, November 1998 (1998-11), pages 1308-1315, XP002260679 ISSN: 0022-3549 *
SIMMONS CARLA G ET AL: "Synthesis and membrane permeability of PNA-peptide conjugates" BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 23, 2 December 1997 (1997-12-02), pages 3001-3006, XP002260678 ISSN: 0960-894X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10501401B2 (en) 2015-09-23 2019-12-10 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10774031B2 (en) 2015-09-23 2020-09-15 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10941107B2 (en) 2015-09-23 2021-03-09 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN110361378A (zh) * 2019-07-25 2019-10-22 浙江大学 基于荧光素乙酯的orac抗氧化活性评价方法及荧光指示剂

Also Published As

Publication number Publication date
WO2004001055A3 (fr) 2004-03-18
AU2003240435A8 (en) 2004-01-06
AU2003240435A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
CA2498772A1 (fr) Molecules pna modifiees
US7550582B2 (en) Polyamide nucleic acid derivatives and agents, and processes for preparing them
JP2758988B2 (ja) ペプチド核酸
JP3326181B2 (ja) 連結ペプチド核酸
AU698210B2 (en) Polyamide-oligonucleotide derivatives, their preparation and use
US6686442B2 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
JP7564087B2 (ja) アンチセンス送達のための三量体ペプチド
AU745309B2 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
US20040072743A1 (en) Pharmaceutical composition of modified pna molecules
MXPA01013114A (es) Conjugados y metodos para la produccion de los mismos, y su uso poara transportar moleculas a traves de membranas biologicas.
US7241882B2 (en) Polyamide nucleic acid derivatives, and agents, and processes for preparing them
US7485421B2 (en) Polyamide-oligonucleotide derivatives, their preparation and use
US20040063906A1 (en) Pna analogues
WO2004001055A2 (fr) Promedicaments a base de pna
CN101547934A (zh) 在线粒体上和线粒体中选择性定位活性剂的方法以及相应的活性剂
WO2002053574A2 (fr) Molecules pna modifiees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP